Abstract:Abstract Background Novartis and the University of Oxford’s Big Data Institute (BDI) have established a research alliance with the aim to improve health care and drug development by making it more efficient and targeted. Using a combination of the latest statistical machine learning technology with an innovative IT platform developed to manage large volumes of anonymised data from numerous data sources and types we plan to identify novel patterns with clinical relevance which cannot be detected by humans alone to identify phenotypes and early predictors of patient disease activity and progression. Method The collaboration focuses on highly complex autoimmune diseases and develops a computational framework to assemble a research-ready dataset across numerous modalities. For the Multiple Sclerosis (MS) project, the collaboration has anonymised and integrated phase II to phase IV clinical and imaging trial data from ≈35,000 patients across all clinical phenotypes and collected in more than 2200 centres worldwide. For the “IL-17” project, the collaboration has anonymised and integrated clinical and imaging data from over 30 phase II and III Cosentyx clinical trials including more than 15,000 patients, suffering from four autoimmune disorders (Psoriasis, Axial Spondyloarthritis, Psoriatic arthritis (PsA) and Rheumatoid arthritis (RA)). Results A fundamental component of successful data analysis and the collaborative development of novel machine learning methods on these rich data sets has been the construction of a research informatics framework that can capture the data at regular intervals where images could be anonymised and integrated with the de-identified clinical data, quality controlled and compiled into a research-ready relational database which would then be available to multi-disciplinary analysts. The collaborative development from a group of software developers, data wranglers, statisticians, clinicians, and domain scientists across both organisations has been key. This framework is innovative, as it facilitates collaborative data management and makes a complicated clinical trial data set from a pharmaceutical company available to academic researchers who become associated with the project. Conclusions An informatics framework has been developed to capture clinical trial data into a pipeline of anonymisation, quality control, data exploration, and subsequent integration into a database. Establishing this framework has been integral to the development of analytical tools.

Voluntary Exploratory Data Submissions to the Us Fda and the Ema: Experience and Impact

Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

The Experience with Voluntary Genomic Data Submissions at the FDA and a Vision for the Future of the Voluntary Data Submission Program

Remote Digital Monitoring for Medical Product Development

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals

Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape

Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis

Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations

Anti-drug Antibody Validation Testing and Reporting Harmonization

Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies

Leveraging patient experience data to guide medicines development, regulation, access decisions and clinical care in the EU

Molecular Biomarkers: A Us Fda Effort

Regulatory and Scientific Issues Regarding Use of Foreign Data in Support of New Drug Applications in the United States: An FDA Perspective

Leveraging Prior Quantitative Knowledge to Guide Drug Development Decisions and Regulatory Science Recommendations: Impact of FDA Pharmacometrics During 2004-2006.

Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital health technologies

Access to regulatory data from the European Medicines Agency: the times they are a-changing

The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach

A Systematic Approach to Biomarker Discovery; Preamble to "the Isbtc-Fda Taskforce on Immunotherapy Biomarkers"

Insights into post-marketing clinical validation of companion diagnostics with reference to the FDA, EMA, PMDA, and MFDS

Asia‐inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler

Development of Genomics-Based Gene Expression Signature Biomarkers in Oncology and Toxicology to Facilitate Drug Discovery and Translational Medicine